Logo image of DERM

JOURNEY MEDICAL CORP (DERM) Stock Price, Quote, News and Overview

NASDAQ:DERM - Nasdaq - US48115J1097 - Common Stock - Currency: USD

6.88  -0.54 (-7.28%)

DERM Quote, Performance and Key Statistics

JOURNEY MEDICAL CORP

NASDAQ:DERM (5/1/2025, 8:55:56 PM)

6.88

-0.54 (-7.28%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High7.84
52 Week Low3.2
Market Cap117.65M
Shares17.10M
Float11.97M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13
IPO11-12 2021-11-12


DERM short term performance overview.The bars show the price performance of DERM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

DERM long term performance overview.The bars show the price performance of DERM in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of DERM is 6.88 USD. In the past month the price increased by 10.26%. In the past year, price increased by 86.45%.

JOURNEY MEDICAL CORP / DERM Daily stock chart

DERM Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 61.08 752.80B
JNJ JOHNSON & JOHNSON 15.37 372.23B
NVO NOVO-NORDISK A/S-SPONS ADR 18.96 291.20B
NVS NOVARTIS AG-SPONSORED ADR 13.21 219.89B
AZN ASTRAZENECA PLC-SPONS ADR 18.95 218.61B
MRK MERCK & CO. INC. 10.69 209.51B
PFE PFIZER INC 7.45 135.72B
SNY SANOFI-ADR 14.02 132.44B
BMY BRISTOL-MYERS SQUIBB CO 6.76 100.94B
GSK GSK PLC-SPON ADR 7.05 78.52B
ZTS ZOETIS INC 26.29 69.43B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.67 47.30B

About DERM

Company Profile

DERM logo image Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Company Info

JOURNEY MEDICAL CORP

9237 E Via De Ventura Blvd., Suite 105, Suite 105

Scottsdale ARIZONA 94025 US

CEO: Thomas G. Wiggans

Employees: 41

Company Website: https://journeymedicalcorp.com/

Investor Relations: http://ir.journeymedicalcorp.com/

Phone: 14804346670

JOURNEY MEDICAL CORP / DERM FAQ

What is the stock price of JOURNEY MEDICAL CORP today?

The current stock price of DERM is 6.88 USD. The price decreased by -7.28% in the last trading session.


What is the ticker symbol for JOURNEY MEDICAL CORP stock?

The exchange symbol of JOURNEY MEDICAL CORP is DERM and it is listed on the Nasdaq exchange.


On which exchange is DERM stock listed?

DERM stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for JOURNEY MEDICAL CORP stock?

10 analysts have analysed DERM and the average price target is 10.07 USD. This implies a price increase of 46.4% is expected in the next year compared to the current price of 6.88. Check the JOURNEY MEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is JOURNEY MEDICAL CORP worth?

JOURNEY MEDICAL CORP (DERM) has a market capitalization of 117.65M USD. This makes DERM a Micro Cap stock.


How many employees does JOURNEY MEDICAL CORP have?

JOURNEY MEDICAL CORP (DERM) currently has 41 employees.


What are the support and resistance levels for JOURNEY MEDICAL CORP (DERM) stock?

JOURNEY MEDICAL CORP (DERM) has a support level at 6.46 and a resistance level at 7.48. Check the full technical report for a detailed analysis of DERM support and resistance levels.


Is JOURNEY MEDICAL CORP (DERM) expected to grow?

The Revenue of JOURNEY MEDICAL CORP (DERM) is expected to grow by 25.96% in the next year. Check the estimates tab for more information on the DERM EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy JOURNEY MEDICAL CORP (DERM) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does JOURNEY MEDICAL CORP (DERM) stock pay dividends?

DERM does not pay a dividend.


When does JOURNEY MEDICAL CORP (DERM) report earnings?

JOURNEY MEDICAL CORP (DERM) will report earnings on 2025-05-13.


What is the Price/Earnings (PE) ratio of JOURNEY MEDICAL CORP (DERM)?

JOURNEY MEDICAL CORP (DERM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).


What is the Short Interest ratio of JOURNEY MEDICAL CORP (DERM) stock?

The outstanding short interest for JOURNEY MEDICAL CORP (DERM) is 2.11% of its float. Check the ownership tab for more information on the DERM short interest.


DERM Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to DERM. When comparing the yearly performance of all stocks, DERM is one of the better performing stocks in the market, outperforming 97.71% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

DERM Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to DERM. DERM has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DERM Financial Highlights

Over the last trailing twelve months DERM reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS decreased by -466.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -18.28%
ROE -73.11%
Debt/Equity 1.24
Chartmill High Growth Momentum
EPS Q2Q%-25%
Sales Q2Q%-10.73%
EPS 1Y (TTM)-466.67%
Revenue 1Y (TTM)-29.1%

DERM Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to DERM. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 72.5% and a revenue growth 25.96% for DERM


Ownership
Inst Owners25.49%
Ins Owners7.91%
Short Float %2.11%
Short Ratio3.21
Analysts
Analysts82
Price Target10.07 (46.37%)
EPS Next Y72.5%
Revenue Next Year25.96%